Naringenin relieves paclitaxel-induced pain by suppressing calcitonin gene-related peptide signalling and enhances the anti-tumour action of paclitaxel.
Chen PanYuhao XuZongsheng JiangChengjiang FanZhexi ChiYu ZhangMengmeng MiaoYuxuan RenZiyi WuLinbin XuChangqing MeiQingge ChenYang XiXiaowei ChenPublished in: British journal of pharmacology (2024)
Naringenin's anti-nociceptive mechanism involves CGRP signalling and neuroimmunoregulation. Furthermore, naringenin facilitates paclitaxel's anti-tumour action, possibly involving apoptosis. This study demonstrates naringenin's potential as a supplementary treatment in cancer therapy by mitigating side effects and potentiating efficacy of chemotherapy.
Keyphrases
- cancer therapy
- neuropathic pain
- chronic pain
- chemotherapy induced
- oxidative stress
- cell death
- genome wide
- pain management
- high glucose
- endoplasmic reticulum stress
- copy number
- diabetic rats
- gene expression
- radiation therapy
- dna methylation
- spinal cord
- transcription factor
- rectal cancer
- replacement therapy
- postoperative pain